Is the pneumococcal vaccine Advance Market Commitment motivating innovation and increasing manufacturing capacity? Some preliminary answers.
作者： Jens Plahte
DOI: 10.1016/J.VACCINE.2012.01.046
关键词: Business 、 Developing country 、 Portfolio 、 Gavi alliance 、 Multinational corporation 、 Marketing 、 Pneumococcal vaccine 、 Productive capacity
摘要: Abstract This paper seeks to give some preliminary evidence on the potential outcome of pneumococcal vaccine Advance Market Commitment (AMC), with a focus its impact innovation in ‘emerging’ manufacturers developing countries. The is derived from series interviews executives at industrial organizations vaccines their R&D portfolio, including both multinational pharmaceutical companies and manufacturers. main findings are that so far there no support any claim AMC speeding vaccines, or it contributing productive capacity expansion. Representatives emerging consistently state either irrelevant inappropriate for supporting innovative activities vaccines.
elsevier.com
sci-hub.se 参考文章(25)
Rachel Glennerster, Michael Kremer, Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases ,(2004)
Michael Kremer, Creating Markets for New Vaccines Part I: Rationale Social Science Research Network. ,(2000)
Anne-Emanuelle Birn, Joel Lexchin, Beyond patents: The GAVI Alliance, AMCs and improving immunization coverage through public sector vaccine production in the global south Human Vaccines. ,vol. 7, pp. 291- 292 ,(2011) , 10.4161/HV.7.3.15217
Geoffrey Targett, Pedro Alonso, Fred Binka, Frank Collins, Brian Greenwood, Janet Hemingway, Feiko ter Kuile, Osman Sankoh, David Schellenberg, Global health and the Bill & Melinda Gates Foundation The Lancet. ,vol. 373, pp. 2195- 2196 ,(2009) , 10.1016/S0140-6736(09)61182-X
Christopher J. Elias, Diverse tools needed to ensure affordable vaccines for the poor Human Vaccines. ,vol. 7, pp. 294- 294 ,(2011) , 10.4161/HV.7.3.15360
Nina Schwalbe, The AMC is helping save children’s lives today Human Vaccines. ,vol. 7, pp. 300- 301 ,(2011) , 10.4161/HV.7.3.15357
Daniel Berman, Rohit Malpani, High time for GAVI to push for lower prices Human Vaccines. ,vol. 7, pp. 290- 290 ,(2011) , 10.4161/HV.7.3.15218
Andrew Farlow, Fixing GAVI’s cash crunch Human Vaccines. ,vol. 7, pp. 295- 296 ,(2011) , 10.4161/HV.7.3.15359
Donald W. Light, Saving the pneumococcal AMC and GAVI. Human Vaccines. ,vol. 7, pp. 138- 141 ,(2011) , 10.4161/HV.7.2.14919